妊娠期糖尿病孕妇体重增长与妊娠结局的关系及影响因素

注册号:

Registration number:

ChiCTR2200063189 

最近更新日期:

Date of Last Refreshed on:

2023-04-07 11:22:54 

注册时间:

Date of Registration:

2022-09-01 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

妊娠期糖尿病孕妇体重增长与妊娠结局的关系及影响因素

Public title:

Relationship between weight gain and pregnancy outcome in pregnant women with gestational diabetes mellitus and influencing factors

注册题目简写:

English Acronym:

研究课题的正式科学名称:

GDM孕妇GWG与HAPO的关系及影响因素

Scientific title:

Relationship between GWG and HAPO in women with GDM and influencing facts

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

贺静 

研究负责人:

汪晖 

Applicant:

He Jing 

Study leader:

Wang Hui 

申请注册联系人电话:

Applicant telephone:

+86 15623181215

研究负责人电话:

Study leader's
telephone:

+86 18380498878

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

jing26@whu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

694703166@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

湖北省武汉市解放大道1095号

研究负责人通讯地址:

湖北省武汉市解放大道1095号

Applicant address:

1095 Jiefang Avenue, Wuhan, Hubei

Study leader's address:

1095 Jiefang Avenue, Wuhan, Hubei

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

华中科技大学同济医学院附属同济医院

Applicant's institution:

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

TJ-IRB20220611

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

华中科技大学同济医学院附属同济医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

伦理委员会批准日期:

Date of approved by ethic committee:

2022-06-13 00:00:00

伦理委员会联系人:

周璞

Contact Name of the ethic committee:

Zhou Pu

伦理委员会联系地址:

湖北省武汉市解放大道1095号

Contact Address of the ethic committee:

1095 Jiefang Avenue, Wuhan, Hubei

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

华中科技大学同济医学院附属同济医院

Primary sponsor:

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

研究实施负责(组长)单位地址:

湖北省武汉市解放大道1095号

Primary sponsor's address:

1095 Jiefang Avenue, Wuhan, Hubei

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖北

市(区县):

武汉

Country:

China

Province:

Hubei

City:

Wuhan

单位(医院):

华中科技大学同济医学院附属同济医院

具体地址:

解放大道1095号

Institution
hospital:

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Address:

1095 Jiefang Avenue

经费或物资来源:

Source(s) of funding:

None

研究疾病:

妊娠期糖尿病  

Target disease:

Gestational Diabetes Mellitus (GDM)

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

1、探究GDM孕妇妊娠期体重增长轨迹对高血糖与不良妊娠结局(Hyperglycemia and Adverse Pregnancy Outcomes, HAPO)的影响; 2、比较美国医学研究所(Institute of Medicine, IOM)指南标准和GDM孕妇不同妊娠阶段体重增长对HAPO的作用; 3、探究社会决定因素对GDM孕妇过度体重增长的影响; 4、探究GDM孕妇孕期体重变化的经历、感受及健康指导需求。  

Objectives of Study:

1. To explore the effects of Pregnancy weight gain trajectory in GDM pregnant women on hyperglycemia and adverse pregnancy outcomes (HAPO); 2. To compare the effects of the Institute of Medicine (IOM) guidelines and the weight gain in women with GDM on HAPO at different stages of pregnancy; 3. To explore the influence of social determinants on excessive weight gain in pregnant women with GDM; 4. To explore the experience, feelings and health guidance needs of GDM pregnant women with weight change during pregnancy.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.孕前已确诊的1型糖尿病和2型糖尿病;
2.新生儿溶血性黄疸等遗传因素导致的病理性黄疸;
3.先天性畸形、死产和新生儿死亡等非活产妊娠 结局;
4.孕前存在严重基础性疾病;
5.孕妇患有传染性疾病。

Exclusion criteria:

1. Type 1 diabetes mellitus and type 2 diabetes mellitus diagnosed before pregnancy;
2. Neonatal hemolytic jaundice and other genetic factors caused by pathological jaundice;
3. Non-live pregnancy outcomes such as congenital malformations, stillbirths and neonatal deaths;
4. Serious underlying diseases existed before pregnancy;
5. Pregnant patients suffer from infectious diseases.

研究实施时间:

Study execute time:

From 2022-09-01 00:00:00 To 2023-08-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-09-01 00:00:00 To 2023-10-01 00:00:00

干预措施:

Interventions:

组别:

GDM组

样本量:

8200

Group:

GDM group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

非GDM组

样本量:

8200

Group:

Non-GDM group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖北 

市(区县):

武汉 

Country:

China

Province:

Hubei

City:

Wuhan

单位(医院):

华中科技大学同济医学院同济医院 

单位级别:

三级甲等 

Institution
hospital:

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆市妇幼保健院 

单位级别:

三级甲等 

Institution
hospital:

Chongqing Health Center for Women and Children

Level of the institution:

Teritary A

国家:

中国

省(直辖市):

湖北 

市(区县):

武汉 

Country:

China

Province:

Hubei

City:

Wuhan

单位(医院):

湖北省妇幼保健院 

单位级别:

三级甲等 

Institution
hospital:

Maternal and Child Hospital of Hubei Province

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖北 

市(区县):

武汉 

Country:

China

Province:

Hubei

City:

Wuhan

单位(医院):

武汉市儿童医院 

单位级别:

三级甲等 

Institution
hospital:

Wuhan Children's Hospital

Level of the institution:

Teritary A

测量指标:

Outcomes:

指标中文名:

巨大儿

指标类型:

主要指标

Outcome:

macrosomia

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

子痫前期

指标类型:

主要指标

Outcome:

preeclampsia

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

剖宫产

指标类型:

主要指标

Outcome:

caesarean section

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

早产

指标类型:

主要指标

Outcome:

premature

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

新生儿低血糖

指标类型:

主要指标

Outcome:

neonatal hypoglycemia

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

新生儿高胆红素血症

指标类型:

主要指标

Outcome:

hyperbilirubinemia

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

新生儿重症监护室

指标类型:

主要指标

Outcome:

neonatal intensive care unit

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

产伤

指标类型:

主要指标

Outcome:

birth injury

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

不适用

Randomization Procedure (please state who generates the random number sequence and by what method):

Not Applicable

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

中国临床试验注册中心;http://www.medresman.org.cn/login.aspx

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Chinese Clinical Trial Registry

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

研究者根据受试者的原始观察记录,将数据完整、正确、清晰的录入病例报告表。录取采用相应的数据库系统双人录入,之后对数据库进行两遍比对。电子数据文件分类保存,并有多个备份保存于不太的磁盘或记录介质上,妥善保管,防止破坏。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

According to the original observation records of the subjects, the researcher input the data into the case report form completely, correctly and clearly. The corresponding database system was used for double entry, and then the database was compared twice. Electronic data files are stored separately and with multiple backups on different disks or recording media for safekeeping and protection against damage.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2022-09-01 22:30:45